Brief: Codexis Announces Enhanced Strategic Focus

Codexis

20/07/2023 21:27

July 20 (Reuters) - Codexis Inc  CDXS.O :
    * CODEXIS ANNOUNCES ENHANCED STRATEGIC FOCUS AND EXTENDS
PROJECTED
CASH RUNWAY TO MID-2026
    * CODEXIS INC: EXPECTS ITS PHARMACEUTICAL MANUFACTURING
BUSINESS
TO RETURN TO GROWTH IN 2024
    * CODEXIS : ORGANIZATION STREAMLINED TO FOCUS ON CONTINUED
ADVANCEMENT AND COMMERCIALIZATION OF ECO SYNTHESIS™ PLATFORM FOR
RNAI THERAPEUTICS PRODUCTION
    * CODEXIS INC: REITERATES 2023 PRODUCT REVENUE GUIDANCE
    * CODEXIS INC: DISCONTINUING INVESTMENT IN CERTAIN
DEVELOPMENT
PROGRAMS, PRIMARILY IN BIOTHERAPEUTICS
    * CODEXIS INC: CONSOLIDATING OPERATIONS TO ITS HEADQUARTERS
AND
REDUCING HEADCOUNT BY APPROXIMATELY 25%
    * CODEXIS INC: PLANNING TO DISCONTINUE ITS 50/50 DEVELOPMENT
SUPPORT OF CDX-7108
    * CODEXIS INC: ACTIVELY EXPLORING OPTIONS TO DRIVE VALUE BY
POTENTIALLY MONETIZING OTHER ASSETS WITHIN ITS BIOTHERAPEUTICS
PORTFOLIO
    * CODEXIS INC: WILL CONSOLIDATE OPERATIONS FROM ITS SAN
CARLOS, CA
FACILITY TO ITS HEADQUARTERS IN REDWOOD CITY, CA
    * CODEXIS INC: SEES Q2 REVENUES ARE EXPECTED TO BE IN RANGE
OF $21
MILLION TO $22 MILLION

Source text for Eikon:  ID:nGNX9WCX4t 
Further company coverage:  CDXS.O 

 ((reuters.briefs@thomsonreuters.com;))